| PCSK9: a key modulator of cardiovascular health NG Seidah, Z Awan, M Chrétien, M Mbikay Circulation research 114 (6), 1022-1036, 2014 | 660 | 2014 |
| Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue A Roubtsova, MN Munkonda, Z Awan, J Marcinkiewicz, A Chamberland, ... Arteriosclerosis, thrombosis, and vascular biology 31 (4), 785-791, 2011 | 292 | 2011 |
| The HDL proteome in acute coronary syndromes shifts to an inflammatory profile K Alwaili, D Bailey, Z Awan, SD Bailey, I Ruel, A Hafiane, L Krimbou, ... Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids …, 2012 | 237 | 2012 |
| Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) AJ Vallejo-Vaz, CAT Stevens, ARM Lyons, KI Dharmayat, T Freiberger, ... The Lancet 398 (10312), 1713-1725, 2021 | 196 | 2021 |
| Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial Z Awan, NG Seidah, JG MacFadyen, S Benjannet, DI Chasman, ... Clinical chemistry 58 (1), 183-189, 2012 | 194 | 2012 |
| PCSK9 and inflammation: a review of experimental and clinical evidence AA Momtazi-Borojeni, S Sabouri-Rad, AM Gotto Jr, M Pirro, M Banach, ... European Heart Journal-Cardiovascular Pharmacotherapy 5 (4), 237-245, 2019 | 151 | 2019 |
| Vascular calcifications in homozygote familial hypercholesterolemia Z Awan, K Alrasadi, GA Francis, RA Hegele, R McPherson, J Frohlich, ... Arteriosclerosis, thrombosis, and vascular biology 28 (4), 777-785, 2008 | 124 | 2008 |
| APOE p. Leu167del mutation in familial hypercholesterolemia Z Awan, HY Choi, N Stitziel, I Ruel, MA Bamimore, R Husa, MH Gagnon, ... Atherosclerosis 231 (2), 218-222, 2013 | 116 | 2013 |
| Simplified Canadian definition for familial hypercholesterolemia I Ruel, D Brisson, S Aljenedil, Z Awan, A Baass, A Bélanger, J Bergeron, ... Canadian Journal of Cardiology 34 (9), 1210-1214, 2018 | 80 | 2018 |
| Decreased PCSK9 expression in human hepatocellular carcinoma M Bhat, N Skill, V Marcus, M Deschenes, X Tan, J Bouteaud, S Negi, ... BMC gastroenterology 15, 1-10, 2015 | 72 | 2015 |
| RETRACTED: Optimized Icariin Phytosomes Exhibit Enhanced Cytotoxicity and Apoptosis-Inducing Activities in Ovarian Cancer Cells NA Alhakamy, UA Fahmy, SM Badr-Eldin, OAA Ahmed, HZ Asfour, ... Pharmaceutics 12 (4), 346, 2020 | 70 | 2020 |
| Inflammation modulation and cardiovascular disease prevention Z Awan, J Genest European Journal of Preventive Cardiology 22 (6), 719-733, 2015 | 70 | 2015 |
| The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomography Z Awan, M Denis, D Bailey, A Giaid, A Prat, D Goltzman, NG Seidah, ... Atherosclerosis 219 (2), 455-462, 2011 | 70 | 2011 |
| RETRACTED: Thymoquinone-Loaded Soy-Phospholipid-Based Phytosomes Exhibit Anticancer Potential against Human Lung Cancer Cells NA Alhakamy, SM Badr-Eldin, UA Fahmy, NK Alruwaili, ZA Awan, ... Pharmaceutics 12 (8), 761, 2020 | 64 | 2020 |
| The effect of insulin on circulating PCSK9 in postmenopausal obese women Z Awan, G Dubuc, M Faraj, R Dufour, NG Seidah, J Davignon, ... Clinical biochemistry 47 (12), 1033-1039, 2014 | 64 | 2014 |
| Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia Z Awan, A Baass, J Genest Clinical chemistry 60 (11), 1380-1389, 2014 | 59 | 2014 |
| Reducing vascular calcification by anti-IL-1β monoclonal antibody in a mouse model of familial hypercholesterolemia Z Awan, M Denis, A Roubtsova, R Essalmani, J Marcinkiewicz, A Awan, ... Angiology 67 (2), 157-167, 2016 | 57 | 2016 |
| High-density lipoproteins and cardiovascular disease: 2010 update K Alwaili, Z Awan, A Alshahrani, J Genest Expert review of cardiovascular therapy 8 (3), 413-423, 2010 | 57 | 2010 |
| Repurposing of some natural product isolates as SARS-COV-2 main protease inhibitors via in vitro cell free and cell-based antiviral assessments and molecular modeling approaches HM Abdallah, AM El-Halawany, A Sirwi, AM El-Araby, GA Mohamed, ... Pharmaceuticals 14 (3), 213, 2021 | 56 | 2021 |
| Dyslipidaemia in the Middle East: Current status and a call for action K Al Rasadi, W Almahmeed, KF AlHabib, M Abifadel, HA Farhan, S AlSifri, ... Atherosclerosis 252, 182-187, 2016 | 56 | 2016 |
